Hearing aids miss CHOICE end point; 70.0% take opioids three months after head and neck radiation; fully implanted cochlear implant debuts in Europe

A round head mirror with a small central hole on an adjustable headband, lying beside an otoscope.

Hearing aids did not significantly reduce conversion from mild cognitive impairment (MCI) to dementia-level impairment in the 703-patient CHOICE trial, published Sept. 28 in JAMA Neurology with an editorial in JAMA Otolaryngology.

An Ohio State cohort found 70.0% of patients still took opioids three months after radiation for head and neck cancer, Med-El launched a cochlear implant with all components under the skin in Europe, and the Food and Drug Administration (FDA) granted breakthrough device designation to a stent for pulsatile tinnitus.

The weekly innovation roundup for otolaryngology, published every Sunday for the week before; every item links to its sources. Latest otolaryngology news · All specialties

Latest news

Tagged otolaryngology, from the daily briefing

  1. Surgical sleep society calls hypoglossal nerve stimulation safe and effective, with surgical response of 67% to 83%
  2. Mindfulness-based interventions eased tinnitus distress with a pooled Hedges g of 0.41 in a meta-analysis
  3. Perioperative camrelizumab plus chemotherapy vs upfront surgery in locally advanced head and neck cancer

See all the latest news